Earnings Call Summary | Biolase(BIOL.US) Q4 2023 Earnings Conference
Earnings Call Summary | Biolase(BIOL.US) Q4 2023 Earnings Conference
The following is a summary of the BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript:
以下是BIOLASE, Inc.（BIOL）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BIOLASE reported a modest increase in net revenue of $49.2 million for the full year compared to $48.5 million in 2022.
Consumable sales record increased by 20% year-over-year.
Gross margin for the year increased by 100 basis points to 34%.
Operating expenses decreased compared to the previous year, standing at $34.7 million for the year compared to $41.2 million in the previous year.
The GAAP net loss for 2023 was $20.6 million as compared to a loss of $28.6 million in 2022.
Adjusted EBITDA loss decreased to $12.8 million from the $20.1 million reported for 2022.
Projected revenues for Q1 2024 are expected to be relatively flat compared to Q1 2023, however, full-year revenue for 2024 is projected to increase by 6% to 8% relative to 2023.
BIOLASE報告稱，與2022年的4,850萬美元相比，全年淨收入略有增長，爲4,920萬美元。
消費品銷售記錄同比增長20％。
該年度的毛利率增長了100個點子，達到34％。
運營支出與去年同期相比有所下降，全年爲3,470萬美元，而去年同期爲4,120萬美元。
2023年的GAAP淨虧損爲2,060萬美元，而2022年的虧損爲2,860萬美元。
調整後的息稅折舊攤銷前利潤虧損從2022年報告的2,010萬美元降至1,280萬美元。
與2023年第一季度相比，預計2024年第一季度的收入將相對持平，但是，預計2024年的全年收入將比2023年增長6％至8％。
Business Progress:
業務進展：
BIOLASE has continued with its commitment to creating awareness of the benefits of laser dentistry, hosting over 500 events, study clubs, webinars, and trade shows in the US alone.
Over 70% of US Waterlase sales are from new customers, and 40% from dental specialists.
Introduction of a recurring revenue subscription model for consumables and strategic partnerships with corporate dentists and academic institutions have boosted adoption of laser dentistry.
BIOLASE plans over 500 education programs and events in 2024 for market adoption growth, and remains confident about improving operational efficiencies and boosting adoption of its dental lasers.
The company is optimistic about its pricing position despite macroeconomic headwinds and expects an improved buying cycle due to stabilizing interest rates.
An affirm commitment to utilizing additional manufacturing capacity at their Corona, California plant to meet any increase in demand.
BIOLASE繼續致力於提高人們對激光牙科好處的認識，僅在美國就舉辦了500多場活動、學習俱樂部、網絡研討會和貿易展。
美國Waterlase的銷售額中有70％以上來自新客戶，40％來自牙科專家。
消費品經常性收入訂閱模式的引入以及與企業牙醫和學術機構的戰略合作伙伴關係促進了激光牙科的採用。
BIOLASE計劃在2024年開展500多個教育項目和活動，以提高市場採用率，並對提高運營效率和促進其牙科激光器的採用充滿信心。
儘管存在宏觀經濟不利因素，但該公司仍對其定價狀況持樂觀態度，並預計由於利率穩定，購買週期將有所改善。
申明承諾利用其位於加利福尼亞州科羅納的工廠的額外製造能力來滿足需求的增長。
More details: Biolase IR
更多詳情： Biolase IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。